Utility of ultrasonography for predicting indications for tolvaptan in patients with autosomal dominant polycystic kidney disease

PURPOSE: Tolvaptan is the first approved treatment for autosomal dominant polycystic kidney disease (ADPKD) that targets a mechanism directly contributing to the development and growth of renal cysts. We investigated the ability of ultrasonography to predict total kidney volume (TKV) of 750 mL or mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Iijima, Hiroko, Tada, Toshifumi, Hashimoto, Mariko, Nishimura, Takashi, Kiriki, Masato, Higashiura, Akiko, Iwasaki, Aya, Honda, Michino, Nagasawa, Yasuyuki, Yamakado, Koichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article–Urology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892067/
https://www.ncbi.nlm.nih.gov/pubmed/36333536
http://dx.doi.org/10.1007/s10396-022-01261-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892067/
https://www.ncbi.nlm.nih.gov/pubmed/36333536
http://dx.doi.org/10.1007/s10396-022-01261-z

Ejemplares similares